Abstract
Lung cancer remains the leading cause of cancer death worldwide and non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer. During the last several decades, tremendous progress in understanding lung cancer biology and development of technology has been achieved, leading to improvement in screening, diagnosis, molecular biology, and management including chemotherapy, targeted therapy and radiotherapy. In this issue,
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
